Table 2 Baseline patient characteristics
From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
Number (%) | |
|---|---|
Age (Median) | 52 |
Gender | |
Male | 12 (60) |
Diagnosis | |
MTC 1 | 7 (35) |
ACC 2 | 5 (25) |
NET 3 | 3 (25) |
Melanoma | 1 (5) |
TCC 4 | 1 (5) |
Prior therapy | 19 (95) |
Surgery | 16 (80) |
Radiation | 10 (50) |
Chemotherapy | 16 (80) |
Prior lines of chemotherapy | |
0 | 4 (20) |
1 | 5 (25) |
2 | 4 (20) |
>2 | 7 (35) |